ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
How to assess and treat congestion in acute heart failure
Prof. Adriaan A. Voors, cardioloogUniversitair Medisch Centrum Groningen
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Disclosures• AAV received consultancy fees Novartis, and
Trevena.• AAV is supported by a grant from the European
Commission: FP7-242209-BIOSTAT-CHF• AAV is supported by research grants from the
Dutch Heart Foundation
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Congestion in Acute Heart Failure
• Congestion is the main reason for hospitalization for worsening HF1
• Most patients admitted to the hospital with ADHF do not achieve adequate relief of signs and symptoms of congestion2
• Patients with inadequate decongestion are known to be at higher risk of readmission for heart failure and mortality2
1. Gheorghiade et al. Eur J Heart Fail 2010; 12, 423–4332. Shakar et al. Curr Treat Options Cardio Med 2014;6:330
ES
C H
F S
evill
a 20
15
University Medical Center Groningen
More weight loss was associated with early dyspnea relief and reduced short-term mortality.
ES
C H
F S
evill
a 20
15
University Medical Center Groningen
How to assess congestion?
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Measurement of congestion• Bedside assessment
• Dyspnea (NYHA, Likert, VAS)• Orthopnea• Rales, Edema, JVP• Body weight
• Laboratory and Radiographic assessment• Natriuretic peptides, BUN, Hemoglobin• Chest X-ray
• Dynamic manoeuvres.• Orthostasis• Valsalva
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen University of Groningen
Treatment of Congestion
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Treatment of Acute Heart Failure
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Total(n=5039)
<85 mmHg(n=90)
85-110mmHg(n-1169
>110 mmHg(n=3484)
I.v. Inotropes 11.9% 73.3% 22.3% 6.8%I.v. Nitrates 20.4% 10.0% 13.3% 23.0%I.v. Diuretics 81.5% 77.8% 82.9% 81.1%
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Goals of Treatment in AHF
McMurray et al. ESC-HF Guidelines; EJHF 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Treatment of Acute Heart Failure
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
PROTECT: design
Prospective, randomized, placebo-controlled study (Rolofylline vs. Placebo) with neutral results
2033 patients admitted with acute HF Daily assessments of diuretic dose and weight Diuretic response was defined as Δ weight kg/40
mg furosemide (or equivalent loop diuretic dose) up to Day 5
Massie et al. NEJM 2010
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Diuretic response and outcome in AHF
Diuretic response (kg/40mg furosemide) –1.7±1 –0.7±0.1 –0.4±0.1 –
0.2±0.1 0.1±0.3 P for trend*
N 349 349 351 347 349
WRF, day 7 21.9% 16% 18.2% 26.8% 25.1% 0.016Persistent WRF 11.7% 10.1% 10.3% 15.5% 17.6% 0.003Worsening heart failure 3.4% 4.9% 5.7% 14.1% 18.3% <0.001
Hemoconcentration on day 4 65.8% 66.4% 61.6% 55.7% 47.1% <0.001
180-day mortality 8.0% 12.6% 14.0% 21.9% 24.9% <0.001
60-day HF re-hospitalisation 7.4% 8.9% 15.7% 19% 23.2% <0.001
60-day death or renal or CV rehosp (%) 15.8% 19.2% 27.9% 35.2% 38.4% <0.001
Valente, et al. EHJ 2014
PROTECT: 2033 AHF patients; serial measurements
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
CARESS-HF• 188 patients hospitalized with acute
decompensated heart failure• Worsened Renal function (increase in serum
Creat >0.3 mg/dL) within 12 weeks before or 10 days after admission
• Signs of congestion• Serum creatinine > 3.0 g/dL excluded• 60 days follow-up• Primary endpoint: change in weight and change
in renal function
Bart et al. NEJM 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
CARESS-HF: primary endpoint
Bart et al. NEJM 2012
96 hours after randomization
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
ROSE-AHF methods• low-dose dopamine may increase urinary output and
preserve renal function in AHF patients
• Multicenter, double-blind, placebo-controlled clinical trial
• 360 hospitalized AHF patients and renal dysfunction (eGFR 15-60 mL/min/1.73m2)
• randomized < 24 hours of admission to low-dose dopamine (2 μg/kg/min)
• Co-primary end points • 72-hour cumulative urine volume (decongestion end point)
• Change in serum cystatin C from enrollment to 72 hours (renal function end point).
Chen et al. JAMA 2013
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
ROSE-AHF: low dose dopamine in AHF
72 hour Urine volume
01,0002,0003,0004,0005,0006,0007,0008,0009,000
10,000
plac
ebo
Urin
ary
Out
put (
L)
P=0.59
dopa
min
edo
pam
ine
Change in Cystatin C
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
plac
ebo
dopa
min
edo
pam
ine
P=0.72
Mg/
dL
N=360 AHF patients with eGFR 15-60 ml/min
Chen et al. JAMA 2013
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Safety• No significant effect of dopamine on secondary
endpoints:• Decongestion• Renal function• Symptom relief
Safety Drug Tolerance Dopamine (n=122)
Placebo (n=119)
P-value
Study drug dose reduced of stopped because of hypotension
0.9% 10.4% <0.001
Study drug dose reduced or stopped because of tachycardia
7.2% 0.9% <0.001
Study drug discontinued due to any cause
23% 25% 0.72
Chen et al. JAMA 2013
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
How to overcome diuretic resistance?
ES
C-H
F S
evill
a 20
15
University Medical Center GroningenTer Maaten et al. Nat Rev Cardiol 2015
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Pre-discharge management
ESC HF Guidelines 2012
ES
C-H
F S
evill
a 20
15
University Medical Center Groningen
Conclusions
• Congestion is the main reason for AHF• Loop diuretics: mainstay decongestion therapy• Inadequate decongestion = poor diuretic
response = poor prognosis• Strategies to improve diuretic response (e.g. add
thiazide, MRA) together with appropriate pre-discharge management may reduce the risk of re-hospitalization